Deadline Approaching on 4/16/18:

NRG NCORP Cancer Prevention and Control (CPC) 

Date Issued: February 19, 2018
Submission Due Date: April 16, 2018
Reply to:  fielde@nrgoncology.org

Summary
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities that will provide data that will directly lead to future Phase II-III  CPC concepts.  As put forward in our core grant, CPC priorities for funding include cancer prevention research and cancer control investigation aimed at understanding and/or ameliorating the symptoms and toxicity related to:

  • immune therapy
  • neurotoxicity
  • cardiotoxicity
  • peripheral neuropathy
  • cancer-related fatigue

Integral to these priorities, are the establishment of biospecimen repositories for molecular studies.

Funding can be requested for up to $18,000 and is contingent upon NRG Oncology’s receipt of the Notice of Award from the Division of Cancer Prevention. One to two projects may be funded.  Projects are to be implemented September 1, 2018 and completed by December 31, 2019. No carry over funds will be issued and an interim progress report is due within 6 months and a completed progress report is due at the end of the project period. Institutions who allow total award to fund research (and waive in-directs) will be given priority.

Background
The NRG NCORP core grant focuses on continued leadership in cancer prevention and control (CPC) research. Our CPC objectives will benefit the NCTN Program through continued research across the breadth of NRG disease sites with a unique focus in both women's health, attributable to our gynecologic and breast cancer expertise, and technology assessment, through the world's largest radiotherapy (RT) focused research base. CPC will design and conduct trials to assess cancer prevention, reduce the burden of cancer treatment-related symptoms across solid tumor disease sites with an emphasis on the prevention of women's cancers, and a focus on high prevalence symptoms in our population.
Instructions for Applicants

If you have an interest in this application, please submit a [5 page proposal to fielde@nrgoncology.org by 5pm ET, Monday, April 16, 2018

  • Description of project, including summary of specific aims
  • How the project will help lead to a Phase II or Phase III NCORP concept
  • Are NRG Oncology resources required? (i.e. biospecimen materials, statistical support, etc)
  • Investigators who will participate in project
  • Timeline [not included in the 5 page limit]
  • NIH biosketch of PI [not included in the 5 page limit]
  • Detailed budget [not included in the 5 page limit]

Submit applications to:
Erica Field
NCORP Administrator
fielde@nrgoncology.org
215-940-8824

Direct scientific questions to NRG NCORP Co-Chairs:
Deborah Watkins Bruner, RN, PhD, FAAN                             

deborah.w.bruner@emory.edu      

Larry Wickerham, MD    

wickerhamd@nrgoncology.org 

Joan Walker, MD                                                                            

Joan-walker@ouhsc.edu

 

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address